Psychotropic properties of a potential anticonvulsant of 5-[(Z)-(4-nitrobenzylidene)]-2- (thiazol-2-ylimino)-4-thiazolidinone

Authors

DOI:

https://doi.org/10.24959/nphj.21.53

Keywords:

thiazolidinone derivatives; psychotropic properties; anticonvulsants

Abstract

Aim. To study the range of psychotropic properties of a new original compound of 5-[(Z)-(4-nitrobenzylidene)]-2-(thiazol-2-ylimino)-4 thiazolidinone with the anticonvulsant activity.

Materials and methods. Adult nonlinear white mice of both sexes weighing 20-27 g were used in the experiments. The locomotor, exploratory, emotional activities were studied in the open field test. The elevated plus maze was used to study anxiety. The effect of the compound on depressive behavior was studied by the tail suspension test. The passive avoidance test was used to study memory. The influence of the compound on the skeletal muscle tone and coordination was studied in the rotarod test. Actoprotective properties were studied in a swimming test with a load of 10 % by weight of the animal.

Results and discussion. In the previous studies, 5-[(Z)-(4-nitrobenzylidene)]-2-(thiazol-2-ylimino)-4-thiazolidinone showed a pronounced anticonvulsant effect in seizure models with different pathogenesis. In this study the related psychotropic effects of the test compound were studied. It was found that in intact mice 5-[(Z)-(4-nitrobenzylidene)]-2-(thiazol-2-ylimino)-4-thiazolidinone in the dose of 100 mg/kg by intragastrical administration did not affect the locomotor, exploratory, emotional activity and its vegetative support, anxiety, depressive activity (in contrast to the reference drug – a classic anticonvulsant sodium valproate, which showed depressive properties), and memory. The test compound did not have a negative effect on the skeletal muscle tone and coordination, but statistically significantly increased the physical endurance of animals, being only slightly inferior to the classic CNS stimulant caffeine.

Conclusions. Thus, 5-[(Z)-(4-nitrobenzylidene)]-2-(thiazol-2-ylimino)-4-thiazolidinone in the dose of 100 mg/kg can be considered as a potential anticonvulsant without related psychotropic effects and with actoprotective properties.

Author Biographies

M. V. Mishchenko , National University of Pharmacy of the Ministry of Health of Ukraine

postgraduate student of the Department of Pharmacology and Pharmacotherapy

S. Yu. Shtrygol’ , National University of Pharmacy of the Ministry of Health of Ukraine

Doctor of Medicine (Dr. habil.), professor, head of the Department of Pharmacology and Pharmacotherapy

A. V. Lozynskyi , Danylo Halytsky Lviv National Medical University

Candidate of Pharmacy (Ph.D.), associate professor of the Department of Pharmaceutical, Organic and Bioorganic Chemistry

R. B. Lesyk , Danylo Halytsky Lviv National Medical University

Doctor of Pharmacy (Dr. habil.), professor, head of the Department of Pharmaceutical, Organic and Bioorganic Chemistry

References

Berg A. T., Altalib H. H., Devinsky O. Psychiatric and behavioral comorbidities in epilepsy: A critical reappraisal. Epilepsia. 2017. Vol. 58, Iss. 7. P. 1123–1130. DOI: https://doi.org/10.1111/epi.13766.

Salpekar J. A., Mula М. Common psychiatric comorbidities in epilepsy: How big of a problem is it? Epilepsy & behavior. 2019. Vol. 98. P. 293–297. DOI: https://doi.org/10.1016/j.yebeh.2018.07.023.

Thiazole-Bearing 4-Thiazolidinones as New Anticonvulsant Agents / M. Mishchenko et al. Scientia Pharmaceutica. 2020. Vol. 88, Iss. 1. P. 16. DOI: https://doi.org/10.3390/scipharm88010016.

Скринінгове дослідження нових похідних тіазолідинону на протисудомну активність / М. В. Міщенко та ін. Запорізький медичний журнал. 2020. Т. 22, № 6. С. 840–846. DOI: https://doi.org/10.14739/2310-1210.2020.6.218463.

Міщенко М. В., Штриголь С. Ю. Спектр антиконвульсантної активності та гостра токсичність 5-[(Z)-(4-нітробензиліден)]-2-(тіазол-2-іліміно)-4-тіазолідинону. Фармакологія та лікарська токсикологія. 2020. Т. 15, №. 6. С. 389–396. DOI: https://doi.org/10.33250/14.06.389.

Drug Discovery and Evaluation: Pharmacological Assays / ed. by F. J. Hock. Springer International Publishing, 2016. 4314 p. URL: https://link.springer.com/referencework/10.1007%2F978-3-319-05392-9.

Руководство по проведению доклинических исследований лекарственных средств. Ч. 1. / под ред. А. Н. Миронова и др. Москва : Гриф и К, 2012. 944 с.

Подольський І. М., Штриголь С. Ю., Гриценко І. С. Вплив перспективного антидепресанта з ноотропними властивостями 2-метил-3-феніламінометилхінолін-4-ону на фази пам’яті. Український журнал клінічної та лабораторної медицини. 2013. Т. 8, № 4. С. 104–107.

Caffeine enhances the antidepressant-like activity of common antidepressant drugs in the forced swim test in mice / A. Szopa et al. Naunyn-Schmiedeberg’s archives of pharmacology. 2016. Vol. 389, Iss. 2. P. 211–221. DOI: https://doi.org/10.1007/s00210-015-1189-z.

Методические рекомендации по статистической обработке результатов доклинических исследований лекарственных средств. Руководство по проведению доклинических исследований лекарственных средств. Ч. 1. / под ред. А. Н. Миронова и др. Москва : Гриф и К, 2012. 944 с.

Xu N., Huggon B., Saunders K. E. A. Cognitive Impairment in Patients with Bipolar Disorder: Impact of Pharmacological Treatment. CNS Drugs. 2019. Vol. 34, Iss. 1. P. 29–46. DOI: https://doi.org/10.1007/s40263-019-00688-2.

Greenblatt H. K., Greenblatt D. J. Gabapentin and Pregabalin for the Treatment of Anxiety Disorders. Clinical Pharmacology in Drug Development. 2018. Vol. 7, Iss. 3. С. 228–232. DOI: https://doi.org/10.1002/cpdd.446.

Kent C. N., Park C., Lindsley C. W. Classics in Chemical Neuroscience: Baclofen. ACS chemical neuroscience. 2020. Vol. 11, Iss. 12. С. 1740–1755. DOI: https://doi.org/10.1021/acschemneuro.0c00254.

Stephen L. J., Wishart A., Brodie M. J. Psychiatric side effects and antiepileptic drugs: Observations from prospective audits. Epilepsy & behavior: E&B. 2017. Vol. 71. С. 73–78. DOI: https://doi.org/10.1016/j.yebeh.2017.04.003.

Downloads

Published

2021-10-19

Issue

No. 2(102) (2021)

Section

Experimental and Clinical Pharmacology

License

Copyright (c) 2021 National University of Pharmacy

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).